SIREN : 532728565
VF BIOSCIENCE is a French company founded 14 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in LOOS (59120), this company of category PME shows in 2023 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | N/C | N/C | 1 617 539 € | 437 028 € | 207 023 € |
| Net income | 0 € | 0 € | 68 124 € | 110 725 € | 2 682 € |
| EBITDA | N/C | N/C | 186 918 € | 165 924 € | -38 635 € |
| Net margin | N/C | N/C | 4.2% | 25.3% | 1.3% |
In 2025, VF BIOSCIENCE records a net loss of 0 €. This deficit will reduce equity on the balance sheet. Change over 2017-2023: 3 k€ -> 0 €.
The debt ratio (= Financial debt / Equity x 100) stands at 52%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 26%. The balance between equity and debt is satisfactory.
52.418%
25.955%
90.2%
In 2025, the debt ratio of VF BIOSCIENCE (52.42) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of VF BIOSCIENCE (25.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2023, the repayment capacity of VF BIOSCIENCE (6.29) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 139.95. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
139.95
In 2025, the liquidity ratio of VF BIOSCIENCE (139.95) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2023, the interest coverage of VF BIOSCIENCE (10.8x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Compare VF BIOSCIENCE with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of VF BIOSCIENCE in 2023 is 1.6 M€.
Yes, VF BIOSCIENCE generated a net profit of 68 k€ in 2023.
The headquarters of VF BIOSCIENCE is located in LOOS (59120), in the department Nord.
The tax return of VF BIOSCIENCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
VF BIOSCIENCE operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.